| Q52725822 | A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials. |
| Q35088234 | A novel cellular senescence gene, SENEX, is involved in peripheral regulatory T cells accumulation in aged urinary bladder cancer |
| Q28727355 | Adoptive transfer of induced-Treg cells effectively attenuates murine airway allergic inflammation |
| Q41233136 | Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice |
| Q52595727 | Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. |
| Q34046489 | Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor |
| Q27028000 | An immunologic portrait of cancer |
| Q43733156 | Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. |
| Q61803775 | Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System |
| Q40366439 | Azacytidine Treatment Inhibits the Progression of Herpes Stromal Keratitis by Enhancing Regulatory T Cell Function |
| Q52966824 | C-terminal cleavage of human Foxp3 at a proprotein convertase motif abrogates its suppressive function. |
| Q50281162 | CD137+CD154- Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from In Vitro Expansion Cultures. |
| Q46762458 | CD26: a negative selection marker for human Treg cells |
| Q37968576 | CD4(+)Foxp3(+) regulatory T cell therapy in transplantation |
| Q97523291 | CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells |
| Q39279238 | Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells |
| Q33778359 | Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-β and retinoic acid |
| Q38201742 | Clinical management of patients receiving cell-based immunoregulatory therapy. |
| Q37912653 | Clinical perspectives for regulatory T cells in transplantation tolerance |
| Q34440616 | Clues to immune tolerance: the monogenic autoimmune syndromes |
| Q91660080 | Coexpression of FOXP3 and a Helios isoform enhances the effectiveness of human engineered regulatory T cells |
| Q47118146 | Combination of IL-2, rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells |
| Q43160329 | Comment on "Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells" Haematologica 2011;96(9):1357-65. |
| Q35195777 | Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3. |
| Q34082794 | Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions |
| Q34994485 | Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. |
| Q39029665 | Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity |
| Q35693630 | Decline of FoxP3+ Regulatory CD4 T Cells in Peripheral Blood of Children Heavily Exposed to Malaria |
| Q37420224 | Detection of Foreign Antigen-specific CD4(+)Foxp3(+) Regulatory T Cells by MHC Class II Tetramer and Intracellular CD154 Staining |
| Q28601365 | Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease |
| Q89748559 | Distinct microbial and immune niches of the human colon |
| Q35762695 | Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. |
| Q34046493 | Driving allotolerance: CAR-expressing Tregs for tolerance induction in organ and stem cell transplantation. |
| Q91260567 | Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells |
| Q45875046 | Engineering Specificity and Function of Therapeutic Regulatory T Cells. |
| Q37412329 | Epigenetic mechanisms of regulation of Foxp3 expression |
| Q51013890 | Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not naïve Treg. |
| Q37962599 | Epigenomics in hematopoietic transplantation: novel treatment strategies |
| Q34424570 | Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia. |
| Q35252405 | Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region. |
| Q54236063 | Expression of Ets-1 and FOXP3 mRNA in CD4(+)CD25 (+) T regulatory cells from patients with systemic lupus erythematosus. |
| Q29307487 | FOXP3+ regulatory T cells in the human immune system |
| Q54473462 | Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects. |
| Q38124117 | Forkhead Box P family members at the crossroad between tolerance and immunity: a balancing act. |
| Q38172563 | Forkhead box P3: the peacekeeper of the immune system. |
| Q47914208 | Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. |
| Q38000883 | Functional plasticity in human FOXP3(+) regulatory T cells: implications for cell-based immunotherapy |
| Q92714308 | Functions of T-cell subsets and their related cytokines in the pathological processes of autoimmune encephalomyelitic mice |
| Q35815893 | HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease |
| Q51539858 | Hepatic stellate cells increase the immunosuppressive function of natural Foxp3+ regulatory T cells via IDO-induced AhR activation. |
| Q36388771 | Heterogeneity and plasticity of T helper cells |
| Q40145396 | Histone methylation mediates plasticity of human FOXP3(+) regulatory T cells by modulating signature gene expressions |
| Q33644234 | Human Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene Transfer |
| Q34626852 | Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns |
| Q34384366 | Human regulatory T cells in autoimmune diseases |
| Q53212253 | Human regulatory T cells suppress proliferation of B lymphoma cells. |
| Q34614309 | Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. |
| Q54427491 | Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. |
| Q47095275 | IL-17A-Producing Foxp3+ Regulatory T Cells and Human Diseases |
| Q33968156 | IL-1β promotes TGF-β1 and IL-2 dependent Foxp3 expression in regulatory T cells. |
| Q36200557 | IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-β7-dependent localization |
| Q37641059 | Immune infiltration in human tumors: a prognostic factor that should not be ignored |
| Q34750481 | Immunomodulatory effects of transforming growth factor-β in the liver |
| Q38194133 | Improving engraftment and immune reconstitution in umbilical cord blood transplantation |
| Q47140596 | In Vivo Attenuation of Antibody-Mediated Acute Renal Allograft Rejection by Ex Vivo TGF-β-Induced CD4+Foxp3+ Regulatory T Cells |
| Q36537036 | In vivo activation of transferred regulatory T cells specific for third-party exogenous antigen controls GVH disease in mice |
| Q36378864 | Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? |
| Q35050808 | Interferon-gamma producing regulatory T cells as a diagnostic and therapeutic tool in organ transplantation |
| Q33999367 | Isolation of purified and live Foxp3+ regulatory T cells using FACS sorting on scatter plot |
| Q61802512 | Kidney Transplant Outcome Is Associated with Regulatory T Cell Population and Gene Expression Early after Transplantation |
| Q34661115 | Lineage stability and phenotypic plasticity of Foxp3⁺ regulatory T cells. |
| Q36551599 | Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity |
| Q92319311 | Mechanisms of human FoxP3+ Treg cell development and function in health and disease |
| Q42117528 | Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells |
| Q41696924 | Mild hypothermia provides Treg stability. |
| Q39380502 | Molecular mechanisms underlying Th1-like Treg generation and function. |
| Q37952092 | Molecular mechanisms underlying the regulation and functional plasticity of FOXP3(+) regulatory T cells |
| Q37881151 | Moving to tolerance: clinical application of T regulatory cells |
| Q42046573 | New tools to expand regulatory T cells from HIV-1-infected individuals. |
| Q90197782 | Next-generation regulatory T cell therapy |
| Q46975760 | Novel Concept of CD4-Mediated Activation of Regulatory T Cells for the Treatment of Graft-Versus-Host Disease. |
| Q38367524 | Now or never? The case for cell-based immunosuppression in kidney transplantation. |
| Q35891619 | Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion |
| Q33561651 | Once a Treg, always a Treg? |
| Q38790694 | Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials |
| Q28081922 | Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells |
| Q50594543 | Origin of Enriched Regulatory T Cells in Patients Receiving Combined Kidney-Bone Marrow Transplantation to Induce Transplantation Tolerance. |
| Q40555716 | Overexpression of CD45RA isoforms in carriers of the C77G mutation leads to hyporeactivity of CD4+CD25highFoxp3+ regulatory T cells |
| Q41140315 | PKC-ѳ is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells |
| Q50130381 | Partial CD25 Antagonism Enables Dominance of Antigen-Inducible CD25high FOXP3+ Regulatory T Cells As a Basis for a Regulatory T Cell-Based Adoptive Immunotherapy. |
| Q92286626 | Peptidase inhibitor 16 identifies a human regulatory T-cell subset with reduced FOXP3 expression over the first year of recent onset type 1 diabetes |
| Q46584678 | Phenotypic analysis of human peripheral blood regulatory T cells (CD4+FOXP3+CD127lo/-) ex vivo and after in vitro restimulation with malaria antigens |
| Q34969823 | Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. |
| Q85185759 | Polyclonal Expansion of Human CD4+CD25+ Regulatory T Cells |
| Q38235166 | Potential and limitations of regulatory T-cell therapy in solid organ transplantation. |
| Q46088131 | Predominance of activated, clonally expanded T helper type 17 cells within the CD4+ T cell population in psoriatic lesions |
| Q38097917 | Promoting transplantation tolerance; adoptive regulatory T cell therapy |
| Q26800184 | Regulatory T Cells in Kidney Transplantation: New Directions? |
| Q47195561 | Regulatory T Cells: From Discovery to Autoimmunity |
| Q26784460 | Regulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in Transplantation |
| Q37900645 | Regulatory T cells and IL-17-producing cells in graft-versus-host disease |
| Q89171054 | Regulatory T cells in autoimmune disease |
| Q38020963 | Regulatory T cells in the central nervous system |
| Q37021703 | Regulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive? |
| Q38557841 | Regulatory T cells: tolerance induction in solid organ transplantation |
| Q30425184 | Regulatory T-Cell (Treg) hybridoma as a novel tool to study Foxp3 regulation and Treg fate |
| Q37309438 | Regulatory T-Cell Therapy for Graft-versus-host Disease |
| Q37855952 | Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity |
| Q27025869 | Regulatory T-cell therapy in transplantation: moving to the clinic |
| Q58694412 | Regulatory immunotherapy in bone marrow transplantation |
| Q35242154 | Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells. |
| Q38963375 | Restoring Regulatory T Cells in Type 1 Diabetes |
| Q93347701 | Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells |
| Q37550184 | Soluble OX40L and JAG1 Induce Selective Proliferation of Functional Regulatory T-Cells Independent of canonical TCR signaling |
| Q35193745 | Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells |
| Q38644779 | Stabilizing human regulatory T cells for tolerance inducing immunotherapy |
| Q38918455 | Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation. |
| Q56447647 | Systemic lupus erythematosus exhibits a dynamic and continuum spectrum of effector/regulatory T cells |
| Q39575774 | T cell signaling targets for enhancing regulatory or effector function |
| Q41939919 | T cell-intrinsic TLR2 stimulation promotes IL-10 expression and suppressive activity by CD45RbHi T cells |
| Q37792312 | T regulatory cells and the control of alloimmunity: from characterisation to clinical application |
| Q43044049 | TGF-β-induced CD4+Foxp3+ T cells attenuate acute graft-versus-host disease by suppressing expansion and killing of effector CD8+ cells. |
| Q37595721 | Targeting Treg cells in situ: emerging expansion strategies for (CD4(+)CD25(+)) regulatory T cells |
| Q46184995 | Targeting the epitope spreader Pep19 by naïve human CD45RA+ regulatory T cells dictates a distinct suppressive T cell fate in a novel form of immunotherapy. |
| Q36075960 | The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. |
| Q35928046 | The molecular mechanisms of regulatory T cell immunosuppression |
| Q37528094 | The plasticity of human Treg and Th17 cells and its role in autoimmunity |
| Q37861024 | The prognostic impact of anti-cancer immune response: a novel classification of cancer patients |
| Q36085059 | The role of all-trans retinoic acid in the biology of Foxp3+ regulatory T cells |
| Q47623651 | The role of regulatory T cells in the regulation of upper airway inflammation |
| Q51014475 | The time is crucial for ex vivo expansion of T regulatory cells for therapy. |
| Q28118511 | The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3 |
| Q52674851 | Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. |
| Q46772183 | Therapeutic application of T regulatory cells in composite tissue allotransplantation. |
| Q34527281 | Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer |
| Q37616428 | Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo |
| Q38000048 | Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease |
| Q58615311 | Tolerising cellular therapies: what is their promise for autoimmune disease? |
| Q39175303 | Transplant genetics and genomics |
| Q27008946 | Treg functional stability and its responsiveness to the microenvironment |
| Q34957397 | Treg vaccination in autoimmune type 1 diabetes |
| Q39836444 | Tregs activated by bispecific antibodies: Killers or suppressors? |
| Q36456483 | Trial watch: Prognostic and predictive value of the immune infiltrate in cancer |
| Q36043724 | Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. |